The text provides comprehensive financial information from Johnson & Johnson and its subsidiaries, including data on their assets, liabilities, shareholders' equity, earnings, and comprehensive income for the fiscal second quarter and six months ended July 2, 2023, compared with the same periods of 2022, reflecting various financial metrics like net earnings, earnings per share, and comprehensive income. It details sales by region and earnings before tax by segment for different segments like pharmaceuticals, MedTech, and Consumer Health, mentioning percentage changes in revenues and expenses, with underlying costs like amortization expenses, restructuring charges, and litigation-related items impacting the financial results. Additionally, it briefly mentions an acquisition of Abiomed on December 22, 2022.
The provided text includes detailed information on the financial performance, operations, and strategic decisions of a company, broken down into segments such as Consumer Health, Pharmaceutical, and MedTech. It gives an overview of sales growth, sales by geographic region, major product franchises, earnings before taxes, analysis of expenses, cash flow, debt levels, recent financial transactions like the separation of the Consumer Health business and the IPO of Kenvue, and future plans to split off Kenvue shares. It also discusses tax implications, initiatives related to accounting pronouncements, and economic factors like the Russia-Ukraine conflict and global healthcare changes affecting the company. Additionally, it outlines specific challenges in terms of intellectual property, government regulations, and changing consumer behavior impacting the company's financial outlook.
The text discusses that there have been no significant changes in the company's assessment of its sensitivity to market risk since the previous disclosure in its Annual Report on Form 10-K for the fiscal year ended January 1, 2023.
The text discusses the evaluation of disclosure controls and procedures of a company, designed to ensure accurate and timely reporting of information required under the Securities Exchange Act. The evaluation concluded that the company's controls and procedures were effective. Additionally, there were no significant changes in the company's internal control over financial reporting during the period covered, and efforts to monitor and assess the effectiveness of disclosure controls and procedures continue.
The text refers to legal proceedings information being included in a specific section of the financial statements document - Note 11 in Part I, Item 1, under the heading of Financial Statements.
I'm sorry, but it seems like there was a misunderstanding. I am unable to summarize the text that you mentioned as I haven't received any parts of the text yet. Could you please provide the text or let me know how I may assist you further?
The Company announced on September 14, 2022, that its Board of Directors approved a share repurchase program of up to $5.0 billion of Common Stock. The repurchase program was completed in the fiscal first quarter of 2023. During the fiscal second quarter of 2023, the Company repurchased a total of 2,357,825 shares of Johnson & Johnson Common Stock through open-market transactions as part of a systematic plan related to the Company's compensation programs. As of April 2, 2023, a total of 30,546,218 shares were purchased for $5.0 billion since the initiation of the repurchase program.
I am ready to assist with the text summarization now. Please go ahead and provide the text you would like me to summarize.
I am ready to summarize the text for you. Please go ahead and provide the text that you would like me to summarize.
I am waiting for the text parts to be sent before summarizing them.
The text provides details about various exhibits filed with a document related to the Securities Exchange Act, Sarbanes-Oxley Act of 2002 certifications, and interactive data files for Johnson & Johnson. It includes certifications by the Chief Executive Officer and Chief Financial Officer, as well as different types of XBRL taxonomy extensions included in the document. The text also includes signatures confirming the authenticity of the report by authorized individuals at Johnson & Johnson, dated July 31, 2023.
